| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01205243 | Infection, Human Immunodeficiency Virus I | Drug: ZIAGEN | ViiV Healthcare|GlaxoSmithKline | | 2010-11-01 | 2015-09-21 |
| NCT02101216 | Psoriasis | Drug: Prurisol|Drug: Ziagen | Cellceutix Corporation | Phase 1 | 2014-03-01 | 2015-03-02 |
| NCT01886638 | HIV|Cardiovascular Disease | Drug: Abacavir | Bayside Health | Phase 4 | 2013-08-01 | 2015-05-21 |
| NCT01973439 | HIV Infection | Other: Intervention 1: PK assessment while on Twice Daily Abacavir|Other: Intervention 2: PK assessment while on Once Daily Abacavir | PENTA Foundation | Phase 1 | 2006-07-01 | 2014-02-03 |
| NCT00765271 | HIV | Drug: Abacavir|Drug: Darunavir/ritonavir|Drug: Raltegravir | St Stephens Aids Trust | Phase 1 | 2008-05-01 | 2009-11-17 |
| NCT01220232 | Healthy Volunteers | Drug: Abacavir/Lamivudine|Drug: Abacavir/Lamivudine|Drug: Lersivirine | Pfizer|ViiV Healthcare | Phase 1 | 2010-11-01 | 2011-02-03 |
| NCT02093585 | HIV | Drug: abacavir (600 mg QD)|Drug: tenofovir (245 mg QD) | Jan Gerstoft|Rigshospitalet, Denmark | Phase 4 | 2014-01-01 | 2015-12-11 |
| NCT01153217 | HIV | Drug: Switch from tenofovir to abacavir | Germans Trias i Pujol Hospital | Phase 3 | 2010-07-01 | 2012-10-16 |
| NCT00002141 | HIV Infections | Drug: Abacavir sulfate | Burroughs Wellcome|NIH AIDS Clinical Trials Information Service | Phase 1 | 1994-07-01 | 2005-06-23 |
| NCT00002197 | HIV Infections | Drug: Abacavir sulfate | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | | | 2005-06-23 |
| NCT00002200 | HIV Infections | Drug: Abacavir sulfate | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | | | 2005-06-23 |
| NCT00002163 | AIDS Dementia Complex|HIV Infections | Drug: Abacavir sulfate | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 3 | | 2005-06-23 |
| NCT00002198 | HIV Infections | Drug: Abacavir sulfate | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 1 | | 2005-06-23 |
| NCT00011479 | HIV Infections | Drug: Abacavir sulfate | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 | | 2012-05-17 |
| NCT00002388 | HIV Infections | Drug: Abacavir sulfate | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 1 | | 2005-06-23 |
| NCT01052701 | Hepatitis C | Other: Ribavrin|Drug: Abacavir plus Ribavirin | Johns Hopkins University|GlaxoSmithKline|University of Nebraska | Phase 1 | 2009-12-01 | 2011-06-22 |
| NCT01656122 | HIV | Drug: abacavir|Drug: 3TC | The HIV Netherlands Australia Thailand Research Collaboration|Radboud University|amfAR, The Foundation for AIDS Research|PHPT/AMS Laboratory, Faculty of Associated Medical Sciences, Chiang Mai University|Chulalongkorn University|ViiV Healthcare | Phase 2|Phase 3 | 2012-07-01 | 2016-02-18 |
| NCT00002390 | HIV Infections | Drug: Abacavir sulfate | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 2 | | 2005-06-23 |
| NCT00314626 | HIV Infections | Drug: efavirenz|Drug: Abacavir+lamivudine | Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA | Phase 3 | 2004-11-01 | 2008-01-25 |
| NCT00002364 | HIV Infections | Drug: Abacavir sulfate | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 2 | | 2005-06-23 |
| NCT02509195 | HIV | Drug: Triumeq | St Stephens Aids Trust|ViiV Healthcare | Phase 4 | 2015-07-01 | 2017-03-16 |
